AN OPEN-LABEL, EXPLORATORY, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF UCB5857 IN SUBJECTS WITH ACTIVATED PHOSPHOINOSITIDE 3 KINASE (PI3K) DELTA SYNDROME (APDS)
Latest Information Update: 22 Dec 2021
At a glance
- Drugs Seletalisib (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions
- Sponsors UCB
- 08 Feb 2019 The trial has been Discontinued in Spain (End Date: 2018-12-13).
- 01 Feb 2019 The trial has been completed in Germany (End Date;2018-12-13).
- 25 Jan 2019 This trial has been completed in France (end date-2018-12-13), according to European Clinical Trials Database.